Volume 9 Issue 5, November 2015

With OC459, a first-in-class, oral, once-a-day small molecule for atopic dermatitis, Atopix has a potential winner for this and other type 2 helper T cell–mediated disorders such as severe asthma and related allergic conditions.

LEO Pharma is focusing on improving outcomes for those living with skin diseases and is seeking new strategic partnerships to change the treatment paradigm in dermatology.

DermTech’s adhesive patch platform enables non-invasive gene expression analysis.

Lipidor’s AKVANO technology is a new delivery method for topical drugs and skin-care treatments that allows them to be applied as a spray.

A commercial environment reinvigorated by improved fundamentals—increased regulatory flexibility and the emergence of exciting new scientific opportunities and innovative business models—has set the stage for a resurgence in the antibiotics space that has already led to an uptick in early-stage venture investment and strategic partnerships.

Helperby’s antibiotic-resistance breakers are a powerful tool serving to prolong and boost antibiotic efficacy and should help counter the growing global crisis of antibiotic resistance.

The London-based translational research company is pioneering the development of innovative imaging biomarkers to enhance efficiency and reduce risk in the development of drugs for therapeutic areas such as inflammation and respiratory disease.

In line with its mission of making the unaffordable accessible worldwide, Pharco Corporation is tackling Egypt’s hepatitis C epidemic.

Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as bispecifics and antibody-drug conjugates is now opening up new opportunities.

F-star is developing a promising pipeline of immuno-oncology therapies with its innovative bispecific antibody technology, which is ideally suited to uncover novel combinatorial biology.

Assisting biopharmaceutical drug discovery and development, particularly with regard to monoclonal antibodies, Sphere Fluidics has developed an integrated platform capable of processing, assaying, sorting and dispensing single cells.

Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach.

Celonic is a private Swiss biotech company specializing in the production of recombinant proteins in mammalian cell systems for use in any stage of drug development

Making encoded library technology a viable alternative to HTS